Sep 27, 2017
MediSieve Shortlisted for Prestigious TCT Awards 2017
The team behind the medical device start-up MediSieve have been nominated for their potentially life-saving magnetic blood filtration device in the Healthcare Application category of the TCT Magazine 2017 Awards.
LONDON – September 27, 2017 – The team behind the medical device start-up MediSieve have been nominated for their potentially life-saving magnetic blood filtration device in the Healthcare Application category of the TCT Magazine 2017 Awards.
MediSieve was nominated for the award thanks to its novel approach to a huge public health issue. The device is an easily applied magnetic sieve which allows for easier treatment of the global killer malaria by directly filtering infected cells from a patient’s bloodstream.
As the device concludes pre-clinical validation and progresses to clinical trials, MediSieve’s experts are now beginning research into ways to broaden the applications of their device, using magnetic particles to target specific disease-causing components in blood. This could include treatments for sepsis and leukaemia.
The TCT Awards judges will look at the category’s contenders and consider how they capitalise on 3D technologies, in particular, the ability to create bespoke one-off parts. They will also look at how they could save lives, whether they reduce costs for healthcare providers and how novel they are. The last criteria are their prospects for future development and their social and educational impact.
George Frodsham, founder and CEO of MediSieve, said: “3D printing had been an invaluable tool for us, particularly when we needed to frequently change small physical aspects of our design. Our Rep Rap 3D printer enabled us to do this easily, quickly and cheaply. I don't know how we would have managed otherwise - it would have been difficult to survive as a start up on a very tight budget.”
The annual TCT Awards cover ten categories and celebrate innovation and collaboration across the R&D sector. Projects which see designers and engineers are of particular interest. The Awards show will be held in September.
The nomination is the latest achievement for the MediSieve team which has already reached the final round of MassChallenge UK 2016, a global non-profit startup accelerator. The team has also enjoyed £350,000 in seed funding from angel investors, received a Pathfinder Award from the Wellcome Trust, won an Innovate UK Smart 2015/16 Proof of Concept Award grant worth £100,000 and secured €50,000 of funding through the EU Horizon 2020 programme.
The team behind the device have also presented at the Royal Society of Medicine's 12th Medical Innovations Summit and been featured in The Telegraph and many other major journals and publications.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: